PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- A recently published clinical study on infusion therapy indicates in-line filters from Pall Corporation (NYSE: PLL) can reduce severe complications and the length of a patient’s stay in the pediatric intensive care unit (PICU). The study1 was featured in Intensive Care Medicine, which is the official journal of The European Society of Intensive Care Medicine and The European Society of Paediatric and Neonatal Intensive Care.
NanodyneTM NEO Intravenous Filter Set
Results from the prospective, randomized clinical trial showed that patients who received infusion solutions through in-line filters had a 25-percent lower overall complication rate than patients without the filter. The length of hospital stay of patients treated with filters also was reduced by nearly a day. Pall filter technology was used in the study, which is listed on the U.S. National Institutes of Health's Clinical Trials database under reference NCT00209768.
According to the study, particulate contamination due to infusion therapy, which typically involves delivering fluids intravenously, poses a potential health risk for intensive care patients. The contamination of infusion solutions by particles is widely unappreciated with underestimated side effects of intravenous (IV) therapy. Complications that can occur from infusion therapy include a systemic inflammatory response syndrome (SIRS), organ failure (circulation, liver, kidney) and thrombosis.
"The trial, the largest clinical IV filtration study to date, clearly demonstrates the safety and efficacy of in-line filtration in preventing major complications during PICU care. It shows that filtration is a preventive strategy to decrease morbidity of critically ill patients and is able to reduce duration of mechanical ventilation and length of stay on PICU,” said Dr. Michael Sasse, the study director from Hannover Medical School. “We believe that in-line filtration is a major step toward improving the safety of infusion therapy."
Just under half (401) of the 807 patients who participated in the study were randomly assigned to a filter group, which received in-line filtration. The remaining participants were assigned to a control group. The study was conducted during a more than three-year period in an interdisciplinary PICU of a tertiary care German hospital. All patients younger than 18 years of age who were admitted to the PICU during the study period were eligible for enrollment.
Pall is a leading supplier of in-line infusion filters to the medical market worldwide. For more information on Pall in-line infusion filters, visit: www.pall.com/IV.
About Pall Corporation
Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.7 billion for fiscal year 2011, is an S&P 500 company with almost 11,000 employees serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
1 Jack T, Boehne M, Brent BE, et al. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med. 2012 Apr 12. [Epub ahead of print] PMID:22527062. DOI 10.1007/s00134-012-2539-7
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50267554&lang=en
Corporate Public Relations
Follow us on Twitter @pallcorporation
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Other Health Research Other Science Science General Health
|NanodyneTM NEO Intravenous Filter Set|